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Background: Patients with alcohol use disorders (AUD) vary significantly in many clini-
cally important characteristics making them a heterogenous group. AUD patients with 
comorbid antisocial personality disorder (ASPD) form an important sub-group, and studies 
indicate that these patients may have poorer treatment outcomes. Therefore, we aimed to 
investigate the characteristics of AUD inpatients with comorbid ASPD and identify predic-
tors of early relapse or treatment drop-out in these patients.
Methods: In a longitudinal study of AUD patients (n = 113; 30 females; aged 27 to 72 
years) in treatment at three residential rehabilitation clinics in Norway, we used interviews 
and self-report questionnaires to collect data on alcohol use, mental health, and trauma 
experience. In addition, we assessed biochemical parameters. The patients were followed 
up at 6 weeks to identify early relapse or drop-out.
Results: Prevalence of ASPD among AUD patients was 15%. AUD patients with comorbid 
ASPD were exclusively male, of younger age, and reported more childhood trauma, and 
adult attention-deficit-hyperactivity-disorder symptoms. They reported more hazardous 
drinking behavior and more often had dependence on substances in addition to alcohol. 
The presence of ASPD did not predict early relapse or drop-out. However, early relapse or 
drop-out in ASPD patients was associated with childhood and adult trauma, younger age of 
drinking debut, and higher baseline prolactin levels.
Conclusion: AUD patients with ASPD had different clinical characteristics to other AUD 
patients and they had specific predictors of early relapse or drop-out. Our findings indicate 
that the early relapse or drop-out among AUD patients with ASPD may be attributed to 
environmental and possibly biological vulnerability. However, further studies with larger 
sample size are warranted to confirm these preliminary associations.
Keywords: alcohol use disorder, antisocial personality disorder, relapse, drop-out
Introduction
Alcohol use disorder (AUD) is a major public health issue. Harmful use of alcohol 
causes 1 in 20 deaths worldwide.1 A systematic analysis for the global burden of 
disease revealed that alcohol use is the seventh leading risk factor for deaths and 
loss of disability-adjusted life-years (DALYs).2 AUD is the most common type of 
substance use disorder in Norway3 with a lifetime prevalence of around seven 
per cent.4 Several effective therapeutic interventions in the treatment of AUD are 
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available5,6 and those who receive professional help for 
AUD have better outcome than those who try to recover 
on their own.7,8 However, the uptake of treatment is low.4,9
More concerning, even after receiving treatment, more 
than half of patients relapse within a year.10,11 Relapse can 
be attributed to several psychosocial and biological fac-
tors. Among others, marital status,12 traumatic 
experiences,13 psychological distress,14 and presence of 
co-existing psychopathology including anxiety, 
depression,15 and attention deficit hyperactivity disorder 
(ADHD)16 may influence relapse. Moreover, relapse may 
be attributed to alcohol-induced neuroadaptation such as 
alteration in the brain dopamine system.17,18 Prolactin, to 
some extent, reflects the activity of the central nervous 
dopamine system as dopamine is a major inhibitor of 
prolactin release.19 Furthermore, it has been found that 
the increase in the level of prolactin is associated with 
more craving20 which is in turn associated with relapse.21
Drop-out is another substantial hindrance in AUD 
treatment.22 Drop-out rates from alcohol treatment pro-
grams have been reported to be over 50%.23 Drop-out is 
related to several factors such as lack of motivation for 
treatment,24 personality factors like lower cooperativeness, 
lower persistence, impulsivity,25 and co-existing 
psychopathology.26 Tools that identify patients at risk are 
being researched pivotally so that drop-out from treatment 
can be prevented.27 There is an unequivocal understanding 
that the entire AUD population cannot be treated as 
a homogenous group. Therefore, endophenotype-focused 
interventions could be beneficial in minimizing relapse or 
drop-out.28
An important endophenotype of AUD are patients with 
comorbid antisocial personality disorder (ASPD).29 ASPD 
is characterized by a life-long pattern of explicit antisocial 
acts with traits of impulsivity, irritability and remorseless-
ness that begin in childhood.30 Although a highly preva-
lent personality disorder31 these patients seldom seek 
treatment32 and if they do, their chances of adhering to 
the treatment are low because of their tendency to violate 
rules.33
AUD is highly prevalent in individuals with ASPD, 
with figures reaching up to 3 in 4.34 The comorbidity 
may be a result of overlapping genetic and environmen-
tal underpinnings.35 Shared environmental risk factors 
such as childhood trauma, coercive parenting and anti-
social peer affiliation is associated with AUD-ASPD 
comorbidity.36 Heritable personality traits like impulsiv-
ity, novelty-seeking and negative emotionality, common 
in ASPD, incapacitate one’s ability to ignore the 
immediate reward offered by alcohol. This jeopardizes 
the ability to inhibit habitual use of alcohol regardless of 
the significant psychological and physical distress it 
causes, leading to the genesis of AUD.29 Conversely, 
excessive alcohol consumption may lead to neuroadapta-
tion that results in increased impulsivity or negative 
emotionality as seen in ASPD.
Comorbid ASPD is associated with greater AUD 
severity37 and represents a special challenge in AUD treat-
ment. The comorbidity leads to poorer treatment 
outcomes38,39 thereby increasing the chance of relapse or 
drop-out25,40 and hence warrants a tailored treatment. 
Thus, it is important to identify the unique factors that 
predicts relapse or drop-out in AUD population with 
comorbid ASPD so that they could be targeted during 
the treatment. The aim of this study is therefore to inves-
tigate the characteristics of AUD patients with comorbid 
ASPD under residential treatment for AUD and identify 
the predictors of early relapse or drop-out in these patients. 
Against this background, our hypothesis is twofold.
1. AUD patients with comorbid ASPD are different 
from those without comorbid ASPD.
2. There are specific factors associated with early 
relapse or drop-out in AUD patients with ASPD.
Materials and Methods
Study Participants
The study participants were patients receiving treatment 
for AUD (n = 113; 30 females) at three different resi-
dential rehabilitation clinics in Norway. These rehabilita-
tion clinics employed abstinence-oriented rehabilitative 
treatment including medications, cognitive behavioral 
therapy, and group therapy. The treatment programs ran-
ged from 3 to 9 months. At the time of study enrollment, 
the participants had been receiving inpatient treatment 
for (median, 25–75 percentiles) 7, 5–12 days and 
reported being abstinent for (median, 25–75 percentiles) 
19, 13–30 days. The patients were between the age of 27 
to 72 years. They were followed up at 6 weeks from the 
baseline. The study was approved by the Norwegian 
Regional Ethics Committee (Reference number 2017/ 
1314). The research complied with the Helsinki 
Declaration. Written informed consent was obtained 
from the patients before enrollment into the study.
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Inclusion and Exclusion Criteria
The inclusion criteria were age of 18 years and older, 
familiarity with a Scandinavian language, currently receiv-
ing inpatient treatment for AUD, self-report of minimum 
of 5 days of abstinence before enrollment into the study, 
and intention to participate in the follow-up at 6 weeks 
from baseline. The patients who were deemed unable to 
provide informed consent or safely participate in the study 
by clinical staff because of psychosis, cognitive impair-
ment, or severe somatic illness were excluded from the 
study. Furthermore, the patients from whom a blood sam-
ple could not be drawn from superficial veins of arm were 
not included in the study.
Measures
Baseline Assessment
Mini International Neuropsychiatric Interview 
Mini International Neuropsychiatric Interview (M.I.N.I) 
Norwegian translation version 6.0 was used to screen 
ASPD and dependence on substances other than alcohol. 
M.I.N.I 6.0 is a short structured diagnostic interview for 
DSM-IV psychiatric disorders. The ASPD module of the 
M.I.N.I is comprised of 12 questions about antisocial beha-
vior and acts with precision between those exhibited before 
and after the age of 15 years. Dependence on substances 
other than alcohol was identified using the non-alcohol 
psychoactive substance use disorders module of the M.I. 
N.I. This module gives the diagnosis of current substance 
dependence and current substance abuse by asking ques-
tions about use of psychoactive substances within the past 
12 months. The diagnosis of either current substance depen-
dence or current substance abuse was considered as depen-
dence on substances other than alcohol in our study.
Biological Measures Related to Alcohol Use and Their 
Analysis 
Phosphatidylethanol (PEth; 16:0/18:1), a direct marker of 
alcohol consumption was examined to identify relapse. In 
addition, other biological measures related to alcohol use 
Gamma-glutamyltransferase (γ-GT) and prolactin were 
also examined.
Venous blood was drawn from the median cubital vein 
in serum gel tubes for γ–GT and prolactin and in ethyle-
nediaminetetraacetic acid (EDTA) tubes for PEth. 
Immediately after the sample collection, the tubes were 
turned upside down about 8 to 10 times. They were then 
set to rest in a blood tube stand. After 30–60 minutes, the 
serum gel tubes were centrifuged to separate the serum. 
The blood samples were then transferred to the laboratory 
to run the required analysis.
PEth was measured by supercritical fluid chromatography- 
mass spectrometry (SFC-MS) using ACQUITY 
Ultraperformance Convergence Chromatography (UPC2) sys-
tem (Waters, Milford, MA, USA). The analytical coefficient of 
variation of the assay was 8.0% and the detection limit was 
0.03 μmol/L.
Psychological Distress Measure 
The Norwegian version of Hopkins Symptom checklist 
(HSCL) with 10 items, previously used in an AUD population, 
was used to identify general mental distress.41 The questions 
in HSCL-10 asked the respondents to identify their experience 
of symptoms related to anxiety and depression over the past 
week on a scale of 1 (not at all) to 4 (extremely). The mean 
score was calculated producing a range of scores from 1 to 4 
where higher score corresponds to more psychological dis-
tress. A study reported that the reliability of the Norwegian 
version of HSCL-10 as tested by Cronbach’s Alpha was 
0.88.42 In the current study, it was 0.90.
Accounts of Trauma 
Accounts of trauma were assessed using a structured self- 
report questionnaire with five questions. This question-
naire has been used previously to interview a psychiatric 
population.37 The first three items asked about traumatic 
experiences in childhood which included sexual assaults, 
physical abuse and other significant traumatic events (3) 
while the last two items asked about traumatic experiences 
in adulthood which included sexual assaults or physical 
abuse (4) and other significant traumatic events (5). For 
each item, the patients could choose: No, Yes, once or Yes, 
several times. The sum score indicating severity of trauma 
was calculated separately for childhood and adulthood 
resulting in a range of score from 0 to 6 for childhood 
trauma and 0 to 4 for adulthood trauma.
The Adult Attention Deficit Hyperactivity Disorder 
Self-Report Scale 
Symptoms of ADHD were assessed using World Health 
Organization (WHO) Adult ADHD Self-Report Scale 
(ASRS).43 It is an 18-item questionnaire based on the 
Diagnostic and Statistical Manual of Mental Disorders 
fourth edition text revision (DSM-IV-TR) criteria. We 
used the six-item screening version of the ASRS that has 
demonstrated better specificity and sensitivity than the full 
version.44 It is scored in a 5-point Likert scale ranging 
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from Never to Very often (4). The sum score was calcu-
lated producing a range of score from 0 to 24 where higher 
score corresponds to more ADHD symptoms. A study 
reported that the reliability of Norwegian version of 
ASRS-6 as measured by Cronbach’s Alpha was 0.64 in 
men and 0.72 in women.45 In our study, for the mixed 
sample of men and women, it was 0.80.
Self-Report Measures on Addiction 
The WHO developed Alcohol Use Disorders Identification 
test (AUDIT) was used to screen hazardous alcohol 
consumption.46 It consists of 10–questions about experi-
ence with alcohol within the last year. Each response has 
scores that range from 0 to 4 which total to a score 
between 0 and 40. A higher score indicates more hazar-
dous alcohol use. A study reported that the reliability of 
the Norwegian version of AUDIT as measured by 
Cronbach’s Alpha was 0.78.47 In our study, it was 0.77. 
In addition to AUDIT, we collected information on 
patients’ age (years) at first alcohol use and history of 
previous AUD treatment.
Follow-Up Assessment
The patients were followed up 6 weeks after the baseline 
assessment. Their level of PEth in the blood sample was 
measured. In addition, the patients who had dropped out of 
the treatment program before the 6-week follow-up were 
identified.
Definition of Early Relapse and Drop-Out
Early Relapse
Early relapse was defined based on changes in the PEth 
values. The PEth concentration at the beginning of abstinence 
influences the time taken for elimination.48 We thus calculated 
the relative decrease in PEth from the baseline to the 6-week 
follow-up by using the formula (PEth at baseline – PEth at 6 
weeks)/(PEth at baseline). PEth generally is considered to 
have terminal elimination half-life (T½) of around 6 days 
but some studies report a T½ of up to 12 days.49 The elimina-
tion time is usually as long as five T½50 and taking the highest 
figure for T½ into consideration, a duration of 60 days (five 
T½ of 12 days) would be required to achieve 100% relative 
change in PEth from baseline. In this early follow-up at 42 
days, we would expect that the relative change in PEth should 
be at least 70%. There were seven patients with less than 70% 
decrease in PEth values from the baseline to the follow-up. In 
addition, one patient had an increased level of PEth at the 
6-week follow-up, resulting in a total of eight relapse cases.
Drop-Out
Patients who discontinued their treatment and left the 
rehabilitation clinics before completion of the planned 
course of treatment were defined as drop-out. Before the 
6-week follow-up, 12 patients dropped out of treatment 
and they were identified as early dropouts.
Studies suggest that one of the main reasons for treat-
ment drop-out is a severe desire to use the substance 
indicating that treatment drop-out is closely related to 
relapse.51 We compared the drop-out group with the 
relapse group and found they did not differ significantly 
in any variables that were measured including background 
variables, psychosocial variables, and both self-report and 
biological variables related to alcohol use. Hence, they 
were considered as a single group for analysis and referred 
as relapse or drop-out group hereafter.
Statistical Analyses
Statistical analyses were performed using SPSS version 23.0 
for Windows. Descriptive statistics were used to present the 
characteristics of the groups with and without ASPD and to 
show the differences in early relapse or drop-out pattern. The 
values were not normally distributed and were therefore pre-
sented as medians and 25–75 percentiles in the tables. Fisher’s 
exact test for categorical variables and Mann Whitney’s U-test 
for continuous variables were used for comparison between 
groups. The effect sizes were reported as odds ratios (OR) for 
categorical variables and as “r” for the continuous variables. 
Cohen’s guidelines were used for interpretation of “r” where 
0.5 and above is a large effect, 0.3 is a medium effect, and 0.1 
is a small effect.52 Furthermore, logistic regression was per-
formed to identify factors that could be characteristic of ASPD 
comorbidity among AUD patients and OR along with 95% 
confidence intervals (CI) were reported. All significant covari-
ates from the unadjusted analysis were included in the adjusted 
logistic regression model. The correlation between all covari-
ates was <0.7. Regression analysis to predict relapse or drop- 
out could not be done due to small sample size in the sub- 
groups. Statistical tests were two-tailed with a significance 
level of α = 0.05.
Results
Difference Between AUD Patients with 
and without Comorbid ASPD
Table 1 presents the differences in characteristics between 
patients with and without ASPD (n = 17 and n = 96, respec-
tively). The patients with comorbid ASPD were exclusively 
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males while those without ASPD included 30 (31.2%) 
females. The median age of patients with ASPD was 39.8 
(25–75 percentiles: 32.7–50.9) years which was lower than 
that of patients without ASPD who had a median age of 54.1 
(48.3–58.5) years (r =0.35, p < 0.001). The patients with 
ASPD had experienced more childhood trauma (r = 0.32, 
p = 0.003) and had more adult ADHD symptoms (r = 0.29, 
p = 0.009). Their median age of drinking debut was 14.0 
(12.0–15.0) years while that of patients without ASPD was 
15.0 (14.0–16.0) years (r =0.18, p = 0.051). The patients with 
ASPD had more hazardous drinking behavior (r =0.25, p = 
0.022) and they more often met criteria for dependence on 
substances other than alcohol (OR = 9.76, p < 0.001). 
However, there was no significant difference in the early 
relapse or drop-out rate between the personality groups at 6– 
week follow-up; 19.5% among the patients without ASPD and 
21.4% among the patients with ASPD (OR = 1.04, p = 1.000).
Table 2 shows the results from the logistic regression 
model (n = 113) of having comorbid ASPD using variables 
that were significant (p < 0.05) in Table 1. A younger age (OR 
= 0.894, 95% CI: 0.806–0.992) and higher childhood trauma 
severity (OR = 2.019; 1.097–3.717) increased the odds of 
ASPD comorbidity when adjusted for one another along with 
ADHD symptoms, hazardous drinking behavior, and depen-
dence on substances other than alcohol.
Factors Associated with Early Relapse or 
Drop-Out in AUD Patients with 
Comorbid ASPD
Table 3 shows the specific factors related to early relapse 
or drop-out in AUD patients with ASPD. In patients with 
comorbid ASPD, those who relapsed or dropped out had 
more psychological distress (r = 0.69, p = 0.040) and had 
Table 1 Differences Between Patients with and without Antisocial Personality in a Cohort of Patients in Treatment for Alcohol Use 
Disorder (n = 113)
AUD Patients without ASPD AUD Patients with ASPD p–values OR or r
n = 96 (85%) n = 17 (15%)
Background
Gender (male) 66 (68.8) 17 (100) 0.006a
Age (years) 54.1 (48.3–58.5) 39.8 (32.7–50.9) <0.001b 0.35
Having paid job as source of income 15 (20.0) 2 (16.7) 1.000a 0.80
Marital status (living with a partner) 21 (27.6) 1 (8.3) 0.281a 0.24
Psychosocial measures
HSCL (mean score) 2.0 (1.5–2.6) 2.2 (1.9–2.5) 0.288b 0.12
Childhood trauma severity 2.0 (0.0–3.0) 4.0 (2.3–4.8) 0.003b 0.32
Adult trauma severity 1.0 (0.0–2.0) 2.0 (0.5–2.0) 0.104b 0.18
ASRS 6 (sum score) 11.0 (9.0–16.0) 16.0 (13.5–18.0) 0.009b 0.29
Self–report measures on addiction
Age at first alcohol use (years) 15.0 (14.0–16.0) 14.0 (12.0–15.0) 0.051b 0.18
AUDIT 29.0 (21.5–33.5) 34.0 (28.3–38.7) 0.022b 0.25
History of previous AUD treatment 62 (65.3) 12 (70.6) 0.785a 1.28
Dependence other substances 14 (14.6) 10 (62.5) <0.001a 9.76
Biological measures for alcohol use at inclusion
γ–GT (U/L) 42.5 (26.0–77.5) 29.0 (20.5–63.0) 0.057b 0.18
PEth (μmol/L) 0.3 (0.1–0.6) 0.2 (0.0–0.6) 0.147b 0.14
Prolactin (mU/L) 133.5 (99.0–186.5) 132.0 (110.0–186.5) 0.753b 0.03
Relapse or drop-out 6 weeks
Relapsed or dropped out at 6 weeks 17(19.5) 3 (21.4) 1.000a 1.04
Notes: Descriptive statistics are presented in the form of number (percentage) for the categorical variables and median (25%–75%) for the continuous variables; aFisher’s 
exact test; bMann Whitney’s U-test; effect sizes are reported as Odds ratio (OR) for categorical variable and as “r” for continuous variables. 
Abbreviations: ASPD, antisocial personality disorder; AUD, alcohol use disorder; HSCL, Hopkins’ Symptom Checklist; ASRS, Adult ADHD Self-Report Scale; AUDIT, 
Alcohol Use Disorder Identification Test; PEth: Phosphatidylethanol and γ-GT: Gamma-glutamyltransferase.
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experienced more childhood and adulthood trauma (r = 
0.70, p = 0.036 and r = 0.76, p = 0.023, respectively). The 
comparison of relapse or drop-out patients across the per-
sonality groups showed that the ASPD patients who 
relapsed or dropped out experienced more childhood and 
adult trauma (r = 0.56, p = 0.35 and r = 0.56, p = 0.037, 
respectively), were younger when they had their first 
experience with alcohol (r = 0.53, p = 0.019), measured 
lower on the level of γ-GT (r = 0.46, p = 0.044), and 
higher on the level of prolactin (r = 0.51, p = 0.025) when 
compared to the patients without ASPD who relapsed or 
dropped out. Figure 1 illustrates the differences in relapse 
or drop-out pattern between the personality groups in 
terms of age of drinking debut, severity of childhood and 
adult trauma, and level of baseline prolactin.
Discussion
In this longitudinal study of AUD patients in treatment, the 
first hypothesis that the AUD patients with comorbid anti-
social personality disorder (ASPD) are different from 
those without comorbid ASPD was confirmed. We found 
that the patients with ASPD were males, of younger age, 
reported more childhood trauma, and more adult ADHD 
symptoms. In addition, patients with ASPD had more 
hazardous drinking behavior, and they more often met 
criteria for dependence on substances other than alcohol. 
Comorbid ASPD in AUD did not predict early relapse or 
drop-out in this study. In line with our second hypothesis, 
we found some specific predictors of early relapse or drop- 
out in AUD patients with ASPD. Their relapse or drop-out 
was more often associated with traumatic experiences, 
younger age of drinking debut, and higher prolactin levels 
at baseline.
The observed male predominance in ASPD is in line 
with other studies.53 This can also be drawn from the 
typologies–focused research in AUD. Among two types 
of AUD patients identified by Cloninger and colleagues, 
Type II AUD patients exhibited antisocial behaviors and 
were predominantly men.54 Our finding of younger age 
among AUD patients with comorbid ASPD corresponds 
with “young antisocial subtype of alcohol dependence”.55 
Moss and colleagues identified five clusters of AUDs in 
a nationally representative sample from the United States. 
Of the five clusters, cluster 4; the young antisocial subtype 
was described, among other things, as a subtype with 
higher probability of having ASPD and a relatively 
young age. Also, AUD patients with comorbid ASPD are 
more likely to seek treatment at a younger age56 which is 
partially reflected in our data because we found that the 
ASPD patients were in treatment at a younger age for the 
current episode of inpatient treatment. However, we do not 
have information on the age at which the patients first 
sought treatment for AUD to confirm the finding of 
Megan and colleagues. We also found that AUD patients 
with ASPD had more adult ADHD symptoms and had 
experienced more childhood trauma, both of which are 
consistent with previous studies.57–60 Furthermore, we 
found that the AUD patients with ASPD had more hazar-
dous drinking behavior which also corresponds to earlier 
findings.61 Antagonism and disinhibition predict hazar-
dous alcohol use62 and antisocial behavior is associated 
with increased lifetime alcohol problems.63 Moreover, we 
found that AUD patients with ASPD more often met 
criteria for dependence on substances other than alcohol. 
In line with our findings, other studies report that comor-
bidity with other substance dependence increases with 
ASPD severity.61 All these findings suggest that antisocial 
Table 2 Logistic Regression Model of Having Comorbid Antisocial Personality Disorder Among Patients in Treatment for Alcohol Use 
Disorder (n = 113)
Reference Unadjusted p-values Adjusted a) p–values
Age Continuous OR (95% CI) 0.89 (0.84–0.95) <0.001 0.89 (0.81–0.99) 0.035
Childhood trauma 
severity
Continuous OR (95% CI) 1.63 (1.15–2.30)) 0.006 2.02 (1.10–3.72) 0.024
ASRS 6 (sum score) Continuous OR (95% CI) 1.23 (1.04–1.46) 0.014 1.31 (0.95–1.79) 0.096
AUDIT (sum score) Continuous OR (95% CI) 1.15 (1.01–1.30) 0.033 1.07 (0.91–1.25) 0.413
Dependence other 
substances
Absence of other substance 
dependence
OR (95% CI) 9.76 (3.06–31.14) <0.001 4.38 (0.62–30.78) 0.137
Notes: a)Adjusted for all significant covariates in the unadjusted analysis; Nagelkerke’s R2 for the multiple regression analysis was 0.577 and the Hosmer-Lemeshow 
goodness of fit test was χ2 = 9.623, df = 8, p = 0.292. 
Abbreviations: OR, odds ratio; CI, confidence Interval; ASRS, Adult ADHD Self-Report Scale; AUDIT, Alcohol Use Disorder Identification Test.
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personality disorder in the AUD population is an important 
but difficult to treat combination that deserves special 
attention.
Many studies corroborate that comorbid ASPD com-
plicates the treatment of AUD.38,64 In our study, however, 
the relapse or drop-out rate did not differ between patients 
with and without ASPD. Other studies have also demon-
strated equal benefits from the alcohol treatment in 
patients with or without ASPD.65 The discrepant findings 
might be due to varying time points in the measurement of 
treatment outcome or different ways of defining treatment 
outcome. However, different factors seemed to predict 
relapse or drop-out in the two different groups.
Relapse or drop-out among the AUD patients with 
ASPD was associated with more lifetime trauma. This is 
partly in line with the finding of Farley et al that relapse in 
Figure 1 Comparison of alcohol use disorder patients (N=96) with and without comorbid antisocial personality in terms of early relapse or drop-out versus treatment 
adherence (No relapse and no drop-out) using Mann Whitney’s U-test. Panel (A) shows age at first drink, panel (B) shows childhood trauma severity, panel (C) shows adult 
trauma severity and panel (D) shows baseline levels of prolactin using mean, standard deviation, and level of significance.
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general is associated with a history of trauma.66 We found 
that among those who relapsed or dropped out, the patients 
with ASPD had an earlier drinking debut. Early age of 
drinking debut is characteristic of ASPD.67 In addition, 
Hingson et al found that younger age of drinking debut 
was associated with chronic relapsing alcohol 
dependence.68 We found that among the patients who 
relapsed or dropped out, those with ASPD had higher 
baseline prolactin levels. Literature suggests that AUD 
patients with ASPD have a heightened dopamine level 
which is related to decreased prolactin levels.69 One pos-
sible explanation for our contradictory finding of higher 
prolactin level in patients with ASPD who relapsed could 
be a tendency of these patients to uphold their dopamine 
homeostasis. In other words, ASPD patients with higher 
prolactin levels relapse possibly because they are biologi-
cally driven to rebound to their conventional state of being 
high in dopamine. This biological drive might also explain 
our finding of earlier drinking debut among ASPD patients 
who relapse compared to other AUD patients.
This is a medium-sized real-life study of patients in 
treatment for AUD involving a comprehensive investiga-
tion of background variables, factors related to vulnerabil-
ity, but also clinically important issues and biochemical 
markers including those related to AUD. Despite its size, 
the study saw only a few relapses or drop-outs in the 
observation period, making the study of patients with 
ASPD vulnerable for under-powering and type II statisti-
cal errors. Caution should be used in interpreting the 
findings. The lower number of relapses or drop-out in the 
study may be due to the patients being treated in residen-
tial treatment clinics. Also, relapse or drop-out was mea-
sured early. Factors related to relapse and drop-out were 
a major focus of our study, but we had no direct assess-
ment of the patients’ motivation to stay sober and stay in 
treatment. There could be other barriers to treatment reten-
tion not measured in our study, including financial pro-
blems, social support, quality of treatment, and staff 
connection issues.
This study implies a need to acknowledge the presence 
of comorbid ASPD in AUD patients as these individuals 
differ on a number of measures compared to other AUD 
patients. Moreover, identification of comorbid ASPD may 
be useful in planning relapse prevention. Additional relapse 
prevention techniques could be tailored to meet the specific 
requirements of patients with ASPD. Lastly, higher biolo-
gical drive towards relapse in patients with ASPD suggests 
that the use of cognitive and behavioral interventions alone 
may not suffice to prevent relapse in this group. Further 
studies on large sample sizes are recommended to confirm 
our preliminary findings on factors related to relapse or 
drop-out in AUD patients with ASPD.
Conclusion
In this study of AUD patients in treatment, 15% met the 
criteria for an antisocial personality disorder. These 
patients were male, of younger age, reported higher child-
hood trauma severity and more hazardous drinking beha-
vior, and they more often had other substance dependence. 
There was no increased risk of early relapse or drop-out 
rate among the patients with ASPD, but they had specific 
predictors of early relapse or drop-out, including earlier 
drinking debut and more life-time trauma. Also, they 
seemed to be more “biologically driven” to drinking, as 
indicated by their increased prolactin levels.
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